HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Supplemental Data All Versions of this Article: fj.08-103275v1 22/9/3389    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Singh, R. Articles by Kostarelos, K. Search for Related Content PubMed PubMed Citation Articles by Singh, R. Articles by Kostarelos, K.

Artificial envelopment of nonenveloped viruses: enhancing adenovirus tumor targeting in vivo

Nanomedicine Laboratory, Centre for Drug Delivery Research, The School of Pharmacy, University of London, London, UK

¹Correspondence: Nanomedicine Laboratory, Centre for Drug Delivery Research, The School of Pharmacy, University of London, 29–39 Brunswick Sq., London WC1N 1AX, UK. E-mail: kostas.kostarelos{at}pharmacy.ac.uk

Recombinant adenovirus (Ad) is a powerful tool in gene therapy. However, the ability to deliver Ad by systemic administration is limited due to rapid clearance from blood circulation, transfection of nontarget tissues, toxicity, and immunogenicity. To address these limitations, we developed an artificially enveloped Ad vector prepared by self-assembly of lipid bilayers around the Ad capsid. The physicochemical and structural features of the enveloped Ad vector can be altered according to the type of lipid used without the need for genetic modification or conjugation chemistry. Here we engineered 4 different types of artificially enveloped Ad using cationic, neutral, fusogenic, and PEGylated lipids to form the envelopes and obtained extended blood circulation times following i.v. administration and reduced vector immunogenicity. Moreover, the PEGylated lipid-enveloped Ad was capable of specifically delivering genes via the systemic circulation to solid tumors subcutaneously implanted in the absence of high levels of gene transfer to the liver and spleen. This provides the basis for the development of a novel vector platform for systemic delivery of Ad to disseminated targets. Furthermore, the artificial envelopment of Ad presented herein is an illustration of a general strategy to modulate the biological function of nonenveloped viruses and may have implications broader than gene therapy.—Singh, R., Tian, B., Kostarelos, K. Artificial envelopment of nonenveloped viruses: enhancing adenovirus tumor targeting in vivo.

Key Words: gene therapy • liposome • cancer • nanoengineering • immunology • nanomedicine

This article has been cited by other articles:

				E. M. Gomes, M. S. Rodrigues, A. P. Phadke, L. D. Butcher, C. Starling, S. Chen, D. Chang, R. Hernandez-Alcoceba, J. T. Newman, M. J. Stone, et al. Antitumor Activity of an Oncolytic Adenoviral-CD40 Ligand (CD154) Transgene Construct in Human Breast Cancer Cells Clin. Cancer Res., February 15, 2009; 15(4): 1317 - 1325. [Abstract] [Full Text] [PDF]